Cardiogen

Heart Research only Animal studies Synthetic short peptide (Cytogen)

Also called AEDR peptide

A four-amino-acid Khavinson peptide associated with heart tissue. Studies report effects on fibroblasts, the cells that handle repair and scarring, and on heart muscle cell growth in aged tissue cultures. One rat study found higher rates of tumor cell death.

Evidence at a glance

Evidence
Animal studies — Not yet studied in people
Status
Research compound only
Dosing
No human study has set a dose

Cell culture from one group. No human trials.

What studies report

How it works

A Khavinson short peptide: at two to four amino acids it is small enough to pass through cell and nuclear membranes intact. The proposed mechanism is that it binds specific sites on nuclear DNA and changes which genes are switched on in its target tissue, rather than acting on a surface receptor the way most peptides do.

Small enough to pass through and act on DNA in the nucleus

Where it acts

Heart

The library groups this compound under Heart. The diagram shows that target, not every tissue it reaches.

Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Heart tissue supportCardiovascular aging

Reasons people seek it out — not a list of proven effects.

Status: Cell-culture and animal data, mostly from one research group.

Route
Subcutaneous injection, or oral capsule depending on the preparation
Sequence
Ala-Glu-Asp-Arg
Formula
C18H31N7O9
Molecular weight
489.5 g/mol
Available as
20 mg
View on PubChem →

Search PubMed for Cardiogen → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.